Brain, Vol. 122, No. 9, 1667-1678,
September 1999
© 1999 Oxford University Press
Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease
1 Department of Radiology, Harvard Medical School, Massachusetts General Hospital, 2 Department of Psychiatry, Tufts University, New England Medical Center, Boston and 3 The Department of Psychiatry and Behavioral Sciences, The Johns Hopkins Medical Institutions, Baltimore, USA
Correspondence to:
Gordon J. Harris, Radiology Computer Aided Diagnostics Laboratory, Gray 2 Room B-285, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA E-mail: harris{at}helix.mgh.harvard.edu
The aim of this study was to examine basal ganglia volumes and regional cerebral blood flow in asymptomatic subjects at-risk for Huntington's disease who had undergone genetic testing. We determined which measures were the best `markers' for the presence of the mutation and for the onset of symptoms. Twenty subjects who were Huntington's disease gene mutation-positive and 24 Huntington's disease gene mutation-negative participants, all of whom had a parent with genetically confirmed Huntington's disease, and were therefore 50% at-risk for inheriting the Huntington's disease gene mutation, were included in the study. To evaluate basal ganglia structure and function, MRI and single photon emission computed tomography (SPECT) were used. Quantitative measures of regional volumes and relative measures of regional perfusion were calculated. SPECT and MRI scans were co-registered so that MRI anatomy could be used accurately to place SPECT regions. Estimated years-to-onset in the mutation-positive subjects was calculated based on a regression formula that included gene (CAG)n repeat length and parental age of onset. Changes in imaging measures in relation to estimated years-to-onset were assessed. The imaging measure that was most affected in mutation-positive subjects was putamen volume. This was also the measure that correlated most strongly with approaching onset. In subjects 
7 years from estimated onset age, the putamen volume measures were similar to those of the mutation-negative subjects. However, in subjects 
6 years from estimated onset age, there were dramatic reductions in putamen volume, resulting in >90% discrimination from both the far-from-onset and the mutation-negative subjects. Caudate volume and bicaudate ratio also showed a significant decline in the close-to-onset subjects, although to a lesser degree than putamen volume reductions. Furthermore, SPECT basal ganglia perfusion deficits were observed in mutation-positive subjects. Imaging markers of neuropathological decline preceding clinical onset are important for assessing the effects of treatments aimed at slowing the course of Huntington's disease. The current study suggests that quantitative assessment of basal ganglia may provide a means to track early signs of decline in individuals with the Huntington's disease gene mutation prior to clinical onset.
MRI; single photon emission computed tomography (SPECT); Huntington's disease; pre-symptomatic; gene-testing
AC = anterior commissure; MMSE = Mini-Mental State Examination; PC = posterior commissure; PCR = polymerase chain reaction; QNE = Quantified Neurological Examination; rCBF = regional cerebral blood flow; SPECT = single photon emission computed tomography; TE = echo time; TR = repetition time
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. C. Knickmeyer, S. Gouttard, C. Kang, D. Evans, K. Wilber, J. K. Smith, R. M. Hamer, W. Lin, G. Gerig, and J. H. Gilmore A Structural MRI Study of Human Brain Development from Birth to 2 Years J. Neurosci., November 19, 2008; 28(47): 12176 - 12182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. De Diego-Balaguer, M. Couette, G. Dolbeau, A. Durr, K. Youssov, and A.-C. Bachoud-Levi Striatal degeneration impairs language learning: evidence from Huntington's disease Brain, November 1, 2008; 131(11): 2870 - 2881. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J S Paulsen, D R Langbehn, J C Stout, E Aylward, C A Ross, M Nance, M Guttman, S Johnson, M MacDonald, L J Beglinger, et al. Detection of Huntington's disease decades before diagnosis: the Predict-HD study J. Neurol. Neurosurg. Psychiatry, August 1, 2008; 79(8): 874 - 880. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Langbehn, J. S. Paulsen, and The Huntington Study Group Predictors of diagnosis in Huntington disease Neurology, May 15, 2007; 68(20): 1710 - 1717. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kin, M. Hirano, T. Taoka, Y. Furiya, H. Kataoka, K. Kichikawa, and S. Ueno Global and Region-Specific Analyses of Apparent Diffusion Coefficient in Dentatorubral-Pallidoluysian Atrophy AJNR Am. J. Neuroradiol., August 1, 2006; 27(7): 1463 - 1466. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C M Kipps, A J Duggins, N Mahant, L Gomes, J Ashburner, and E A McCusker Progression of structural neuropathology in preclinical Huntington's disease: a tensor based morphometry study J. Neurol. Neurosurg. Psychiatry, May 1, 2005; 76(5): 650 - 655. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Paulsen, J. L. Zimbelman, S. C. Hinton, D. R. Langbehn, C. L. Leveroni, M. L. Benjamin, N. C. Reynolds, and S. M. Rao fMRI Biomarker of Early Neuronal Dysfunction in Presymptomatic Huntington's Disease AJNR Am. J. Neuroradiol., November 1, 2004; 25(10): 1715 - 1721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. H. Aylward, B. F. Sparks, K. M. Field, V. Yallapragada, B. D. Shpritz, A. Rosenblatt, J. Brandt, L. M. Gourley, K. Liang, H. Zhou, et al. Onset and rate of striatal atrophy in preclinical Huntington disease Neurology, July 13, 2004; 63(1): 66 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Kassubek, F D Juengling, T Kioschies, K Henkel, J Karitzky, B Kramer, D Ecker, J Andrich, C Saft, P Kraus, et al. Topography of cerebral atrophy in early Huntington's disease: a voxel based morphometric MRI study J. Neurol. Neurosurg. Psychiatry, February 1, 2004; 75(2): 213 - 220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Thieben, A. J. Duggins, C. D. Good, L. Gomes, N. Mahant, F. Richards, E. McCusker, and R. S. J. Frackowiak The distribution of structural neuropathology in pre-clinical Huntington's disease Brain, August 1, 2002; 125(8): 1815 - 1828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yamada, R. G. Gonzalez, L. Ostergaard, S. Komili, R. M. Weisskoff, B. R. Rosen, W. J. Koroshetz, T. Nishimura, and A. G. Sorensen Iron-Induced Susceptibility Effect at the Globus Pallidus Causes Underestimation of Flow and Volume on Dynamic Susceptibility Contrast-Enhanced MR Perfusion Images AJNR Am. J. Neuroradiol., June 1, 2002; 23(6): 1022 - 1029. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Klapstein, R. S. Fisher, H. Zanjani, C. Cepeda, E. S. Jokel, M.-F. Chesselet, and M. S. Levine Electrophysiological and Morphological Changes in Striatal Spiny Neurons in R6/2 Huntington's Disease Transgenic Mice J Neurophysiol, December 1, 2001; 86(6): 2667 - 2677. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-Y. Hsu, A.-T. Du, N. Schuff, and M. W. Weiner Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy in Dementias J Geriatr Psychiatry Neurol, September 1, 2001; 14(3): 145 - 166. [Abstract] [PDF]
|
|